Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.
A Pilot Pharmacodynamic/Pharmacokinetic Study of SalmeterolXinofoate as a Dry Powder in Combination with Fluticasone in Patients with Asthma for Dose-Scale Bronchodilator Model Development.
A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma.
100 Clinical Results associated with Oriel Therapeutics, Inc.
0 Patents (Medical) associated with Oriel Therapeutics, Inc.
01 Apr 2007·POWDER TECHNOLOGY
Precision powder metering utilizing fundamental powder flow characteristics
Author: Crowder, Timothy M.
A proof of concept prototype was constructed to test the capabilities of using vibration frequencies determined from rotating drum powder flow characterization to reproducibly fill small unit doses of pharmaceutical powders.A lactose excipient was characterized in the rotating drum and a multiperiodic vibration signal determinedDoses ranging from 1.5 to 16 mg were metered from the system.The prototype used vibrational fluidization to meter powders under the influence of gravity.Vibration frequencies calculated from phys. characterization of the powders had a significant influence on the reproducibility of metering with relative standard deviations around the mean as low as 2% and no greater than 5%.Future work will address limitations to the system that introduced systematic errors and will address addnl. formulation variables.
100 Deals associated with Oriel Therapeutics, Inc.
100 Translational Medicine associated with Oriel Therapeutics, Inc.